相关临床试验
2
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
尚未招募
2
100.0%
暂无批准数据
- Researchers at UT MD Anderson Cancer Center found that psilocybin given before chemotherapy prevented chemotherapy-induced peripheral neuropathy across several preclinical models, even after repeated treatment cycles. - The neuroprotective effect is mediated through serotonin 5-HT2A receptors, which preserve mitochondrial trafficking and energy delivery to nerve endings without interfering with chemotherapy's antitumor activity. - Blocking the 5-HT2A pathway reversed the protection, while a non-hallucinogenic compound activating the same receptors produced similar neuroprotection, suggesting a first-in-class preventive approach. - These findings support an upcoming Phase 2 clinical trial (NeuroGuard, NCT07227909) evaluating psilocybin during chemotherapy in patients with multiple cancer types.
- Researchers identified TRNAU1AP as a key protein driving glioblastoma stem cell survival, with elevated levels correlating to worse patient outcomes. - TRNAU1AP forms intracellular clusters that promote selenoprotein synthesis, protecting cancer stem cells from oxidative damage and therapy resistance. - The m6A reader protein IGF2BP3 stabilizes TRNAU1AP mRNA, and blocking the IGF2BP3-TRNAU1AP axis may render glioblastoma cells more vulnerable to treatment. - Lead investigator Suyun Huang aims to develop blood-brain barrier-penetrant small-molecule IGF2BP3 inhibitors as a potential therapeutic strategy.
- A small population of immature NK cells in donor cord blood can undermine CAR NK cell therapy by redirecting therapeutic cells away from tumors through trogocytosis. - Immature NK cells pick up cancer proteins and become false targets, causing engineered CAR NK cells to attack one another instead of tumors. - Removing immature NK cells before manufacturing improved CAR NK cell function, persistence, and antitumor activity in preclinical lymphoma and ovarian cancer models. - The study, published in Cancer Cell, offers a practical manufacturing strategy to enhance the potency and consistency of off-the-shelf NK cell therapies.
- Researchers at MD Anderson Cancer Center developed an AI-assisted technique that identifies all tumor-feeding arteries to improve intra-arterial therapy delivery for malignant brain tumors. - The multi-pedicle approach achieved more than 85% tumor coverage in all three treated patients, compared to less than 65% with traditional single-artery infusion. - The AI-guided method creates patient-specific maps of tumor blood supply, enabling precise, tailored dosing to each feeding artery while reducing off-target delivery. - The procedure was safely repeated two weeks later, though additional studies are needed to determine whether improved tumor coverage translates to better patient outcomes.
- A 24-hour fast increases the gut bacterium Akkermansia muciniphila (AKK), which produces propionate that primes intestinal cells for regeneration after radiation damage. - Preclinical research from MD Anderson Cancer Center shows fasting and AKK work together to modify histones, exposing genes linked to tissue repair before injury occurs. - Removing AKK eliminated the protective benefit of fasting, and restoring the bacterium alone was insufficient — both fasting and AKK were required for the regenerative response. - The findings could lead to dietary or microbe-based strategies that protect healthy tissue during abdominal cancer radiation without requiring patients to fast.
- Preoperative radiation therapy activates immune pathways in brain metastases, transforming the immunosuppressed tumor microenvironment into one more receptive to immunotherapy. - An integrated profiling analysis of 306 patient tissue samples revealed radiation enhances T cell receptor diversity and recruits cytotoxic T cells into tumors. - Researchers identified T cell receptor diversity in the tumor microenvironment as a potential prognostic biomarker for predicting treatment response. - Findings provide a strong biological rationale for radiation-immunotherapy combination strategies, with validation now underway in larger prospective clinical trials.
- The FDA announced a pilot program to monitor clinical trial data in real-time, starting with cancer studies from AstraZeneca and Amgen to expedite drug development timelines. - AstraZeneca's Phase 2 trial targets untreated mantle cell lymphoma patients while Amgen's Phase 1b study focuses on small cell lung carcinoma treatment. - The initiative aims to reduce the traditional 10-12 year drug development timeline by allowing FDA regulators to view safety signals and clinical endpoints as they occur. - Officials hope real-time monitoring will enable quicker feedback on drug efficacy and safety concerns, potentially accelerating approval processes for promising therapies.
- Purdue Pharma and GCAR have initiated enrollment of tinostamustine in the GBM AGILE adaptive platform trial for newly diagnosed and recurrent glioblastoma patients. - Tinostamustine represents a first-in-class therapeutic combining DNA alkylating activity and HDAC inhibition to target both genomic instability and epigenetic dysregulation in aggressive brain cancers. - The GBM AGILE trial's innovative design enables multiple therapies to be evaluated simultaneously against a shared control arm, potentially supporting future FDA registration. - Since 2019, the international platform has screened over 2,600 patients across approximately 60 trial locations in six countries, addressing the urgent need for new glioblastoma treatments.
- Cleveland Clinic researchers discovered that elevated bacterial levels within head and neck cancer tumors suppress immune response and drive resistance to immunotherapy, shifting focus beyond tumor genetics to the tumor microbiome. - Analysis of the CIAO clinical trial revealed that tumor bacterial burden was the only significant predictor of immunotherapy response, outperforming traditional biomarkers like PD-L1 staining and tumor mutational burden. - Preclinical studies demonstrated that antibiotics reduced tumor size and improved immune response by decreasing neutrophil infiltration and increasing T cell presence, while bacterial administration made tumors resistant to anti-PD-L1 treatment. - The findings suggest that targeting intratumoral bacteria through antibiotic therapy could potentially restore immunotherapy effectiveness in non-responding patients, with clinical trials already underway to test this approach.
- Cancer patients who received Pfizer or Moderna COVID-19 vaccines within 100 days of starting checkpoint inhibitor therapy were twice as likely to survive three years compared to unvaccinated patients. - The survival benefit was particularly pronounced in patients with "cold" tumors that typically don't respond well to immunotherapy, showing nearly fivefold improvement in three-year survival. - Preclinical studies revealed that mRNA vaccines increase type I interferon production and PD-L1 expression on tumors, potentially enhancing the immune system's ability to fight cancer. - Researchers are preparing a nationwide clinical trial to test this combination approach in lung cancer patients receiving immune checkpoint inhibitors.
